Tuberculosis in the elderly

Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach, Third Edition

Volumn , Issue , 2006, Pages 345-370

  Davies, Peter D O ^a   Moore Gillon, John ^b   Woo, Jean ^c  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951481192     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (88)

1. http://www.censusscope.org/us/chart_age.html (accessed 28/7/04, no date for update).
2. http://www.statistics.gov.uk/cci/nugget.asp?id=763 (updated 24/6/04, accessed 28/7/04).
3. http://www.stats.govt.nz/domino/external/web/prod_serv.nsf/0/ce9f1956abbe70f3 cc256d4e007370a1?OpenDocument (accessed 28/7/04).
4. Davies PDO. The increase in tuberculosis. Ann Med 2003; 35:235-243.
5. Reider HL. Epidemiology of tuberculosis in Europe. Eur Resp J 1995; 20(suppl 8): 205-325.
6. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Org 1992; 70:149-159.
7. Rose AMC, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56:173-179.
8. Springett VH. An interpretation of statistical trends in tuberculosis. Lancet 1952; 1:521-525.
9. Medical Research Council. Cardiothoracic Epidemiology Group. National survey of notifications of tuberculosis in England and Wales in 1988. Thorax 1992; 47:770-775.
10. Andvord KF. What can we learn by studying tuberculosis by generations? 1930 Norsk Mag. Laegevidensk 1930; 91:642-660.
11. Frost WH. Age selection of mortality from tuberculosis in successive decades. Am J Hyg 1939; A30:91-96.
12. Springett VH. A comparative study of tuberculosis mortality rates. J Hyg 1950; 48:361-395.
13. Tocque K, Bellis MA, Tam CM, et al. Long-term trends in tuberculosis: comparison of age-cohort data in Hong Kong and England and Wales. Am J Resp Crit Care Med 1998; 158:484-488.
14. Nisar M, Williams CSD, Ashby D, Davies PDO. Tuberculin screening of residential homes for the elderly. Thorax 1993; 48:1257-1260.
15. Daynes RA, Enioutina EY, Jones DC. Role of redox imbalance in the molecular mechanisms responsible for immunosenescence. Antioxid Redox Signal 2003; 5:537-548.
16. Enioutina EY, Visic VD, Daynes RA. Enhancement of common mucosal immunity in aged mice following their supplementation with various antioxidants. Vaccine 2000; 18:2381-2393.
17. Jones DC, Manning BM, Daynes RA. A role for the peroxisome proliferation-activated receptor alpha in T-cell physiology and ageing immunology. Proc Nutr Soc 2002; 61:363-369.
18. Morris CD, Nell H. Epidemic of pulmonary tuberculosis in geriatric homes. S Afr Med J 1989; 75:197.
19. Woo J, Chan HS, Hazlett CB, et al. Tuberculosis among elderly Chinese in residential homes: tuberculin reactivity and estimated prevalence. Gerontology 1996; 42:155-162.
20. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Eng J Med 1985; 312:1483-1487.
21. Perez-stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. Conversion and reversion of tubrculin reactions in nursing home residents. Am Rev Respir Dis 1988; 137:801-804.
22. Yoshikawa TT. Tuberculosis in aging adults. J Am Geriatr Soc 1992; 40:178-187.
23. Zevallos M, Justman JE. Tuberculosis in the elderly. Clin Geriatr Med 2003; 19(1):121-138.
24. Katz PR, Reichman W, Dube D, Feather J. Clinical features of pulmonary tuberculosis in young and old veterans. J Am Geriatr Soc 1987; 35:512-515.
25. Umeki S. Comparison of younger and elderly patients with pulmonary tuberculosis. Respiration 1989; 55:75-83.
26. Tsai S-Y, Huang M-S, Hwang J-J, et al. Comparison of pulmonary tuberculosis in younger and elderly patients. Kaohsiung J Med Sci 1991; 7:107-114.
27. Van den Brande P, Demetdts M. Pulmonary tuberculosis in the elderly: diagnostic difficulties. Eur J Med 1992; 14:224-229.
28. Teale C, Goldman JM, Pearson SB. The association of age with presentation and outcome of tuberculosis: a five-year survey. Age Aging 1993; 22:289-293.
29. Korzeniewska-Kosela M, Krysl J, Muller N, Black W, Allen E, FitzGerald JM. Chest 1994; 106:28-32.
30. Sime PJ, Chilvers ER, Leitch AG. Miliary tuberculosis in Edinburgh—A comparison between 1984-1992 and 1954-1987. Respir Med 1994; 88:609-611.
31. Chin NK, Kumarashinge G, Lim TK. Efficacy and the conventional diagnostic approach to pulmonary tuberculosis. Singapore Med J 1998; 39:241-245.
32. Chan CHS, Woo J, Or KKH, Chan RCY, Cheung W. The effect of age on the presentation of patients with tuberculosis. Tuberc Lung Dis 1995; 76:290-294.
33. Humphries MJ, Byfield SP, Darbyshire J, et al. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest 1984; 78:149-158.
34. Nisar M, Davies PDO. Current trends in mortality from tuberculosis in England and Wales. Thorax 1991; 46:438-440.
35. Doherty MJ, Spence DPS, Davies PDO. Trends in tuberculosis in England and Wales: the proportion of deaths from non-respiratory disease is increasing in the elderly. Thorax 1995; 50:976-979.
36. Martineau A, Lowey H, Tocque K, Davies PDO. Case fatality from tuberculosis by age and site in England and Wales. Int J Tuberc Lung Dis 2004; 8:732-742.
37. MacGee W. The frequency of unsuspected tuberculosis found post-mortem in a geriatric population. Z Gerontol 1989; 22:311-314.
38. Zafran N, Heldal E, Pavlovic S, Vuckovic D, Boe J. Why do our patients die of active tuberculosis in the era of effective chemotherapy? Tuberc Lung Dis 1994; 75:329-333.
39. Bakhshi SS, Hawker J, Ali S. Tuberculosis mortality in notified cases from 19891995 in Birmingham. Publ Health 1988; 112:165-168.
40. Borgdoff MW, Veen J, Kalisvaart NA, Nagelkerke N. Mortality among tuberculosis patients in the Netherlands in the period 1993-1995. Eur Respir J 1998; 11: 816-820.
41. Lawn SD, Acheampong JW. Pulmonary tuberculosis in adults: factors associated with mortality at a Ghanaian teaching hospital. West Afr J Med 1999; 18: 270-274.
42. Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for an acceptable treatment success rates. Int J Tuberc Lung Dis 2002; 6:1114-1117.
43. Wallace JI, Paauw DS, Spach DH. HIV infection in older patients: when to suspect the unexpected. Geriatrics 1993; 48:61-70.
44. Newcomer VD. Human immunodeficiency virus infection and acquired immunodeficiency syndrome in the elderly. Arch Dermatol 1997; 133:1311-1312.
45. Manfredo R. HIV infection and advanced age: emerging epidemiological, clinical and management issues. Ageing Res Rev 2004; 3:31-54.
46. Laszlo A, Gianelli S, Laurencet F, Krause KH, Janssens JP. Successful treatment of disseminated tuberculosis and acquired immunodeficiency syndrome in an 81-yr-old woman. Scand J Infect Dis 2003; 35:420-422.
47. Gebo KA, Moore RD. Treatment of HIV infection in the older patient. Expert Rev Anti Infect Ther 2004; 2:733-743.
48. Mackay AD, Cole RB. The problems of tuberculosis in the elderly. Q J Med 1984; 212:497-510.
49. Holdiness MR. Clinical pharmacokinetics of the antituberculous drugs. Clin Phar-macokinet 1984; 9:511-544.
50. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy men. Hepatology 1989; 9:297-301.
51. Bach B, Hausen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of anti-pyrine and phenytoin correlated with age and liver volume in man. Clin Pharmaco-kinet 1981; 6:389-396.
52. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 7:49-54.
53. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4:401-422.
54. Iselius L, Evans DA. Formal genetics of isoniazid metabolism in man. Clin Pharma-cokinet 1983; 8:541-544.
55. Advenier C, Saint-Aubin A, Gorbert C, Houin G, Albengres E, Tillement JP. Pharmacokinetics of isoniazid in the elderly. Br J Clin Pharmacol 1980; 10: 167-168.
56. Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol 1986; 30:335-340.
57. Paulsen O, Nilsson LG. Distribution of acetylator phenotype in relation to age and sex in Swedish patients. Eur J Clin Pharmacol 1985; 28:311-315.
58. Advenier C, Gobert C, Houin G, Bidet D, Richelet S, Tillement JP. Pharmacokinetics studies of rifampicin in the elderly. Ther Drug Monit 1983; 5:61-65.
59. Walubo A, Chan K, Woo J, Chan HS, Wong CL. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. Methods Find Exp Clin Pharmacol 1991; 13:551-556.
60. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-47.
61. Woodford-Williams E, Alvarez AS, Webster D, Landless B, Dixon MP. Serum protein patterns in “normal” and pathological ageing. Gerontologia 1964; 10:86-99.
62. Verbeek RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 24:91-97.
63. Upton RA, Williams RL, Kelly J, Jones RM. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984; 18:207-214.
64. Umeki S. Age-related changes in the manifestations of tuberculosis. Implications for drug therapy. Drugs Aging 1991; 1:440-457.
65. Riska N. Hepatitis cases in isoniazid treated group and in a control group. Bull Int Union Tuberc 1976; 51:203-208.
66. Gangadharam PRJ. Isoniazid, rifampicin and hepatotoxicity. Am Rev Resp Dis 1986; 133:963-965.
67. Back KC, Thomas AA. Aerospace pharmacology and toxicology. Ann Rev Pharmacol 1970; 10:396-397.
68. Blair LA, Tinoco RM, Brodie MJ, et al. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Human Toxicol 1985; 4:195-202.
69. Walubo A, Chan K, Woo J, Chan HS, Wong CL. The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite. Methods Find Exp Clin Pharmacol 1991; 13:545-550.
70. Woo J, Chan HS, Walubo A, Chan K. Hydrazine: a possible cause of isoniazid-induced hepatic necrosis. J Med 1992; 23:51-59.
71. Lees AW, Allan GW, Smith J, Tyrrell WF, Fallon RJ. Toxicity of rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52:182-190.
72. Centers for Disease Control. Adverse drug reactions among children treated for tuberculosis. MMWR 1980; 29:589-591.
73. Jenner PJ, Ellard GA. Isoniazid-related hepatotoxicity: a study of the effect of rifam-picin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70:93-101.
74. Sarma GR, Immanuel C, Kailasam S, Narayana ASL, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. Am Rev Respir Dis 1986; 133: 1072-1075.
75. Chan CHS, Or KKH, Cheung W, Woo J. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin. J Med 1995; 26:43-52.
76. Farer LS, Lowell LM, Meador MP. Extrapulmonary tuberculosis in the United States. Am J Epidemiol 1979; 109:205-217.
77. Campbell TC, Hayes JR. Role of nutrition in the drug-metabolising enzyme system. Pharmacol Rev 1974; 26:171-197.
78. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculous infection. N Engl J Med 2002; 347:1860-1866.
79. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum pathology and probable pathogenesis. Ann Intern Med 1976; 84:181-192.
80. Girling DJ. The hepatic toxicity of anti-tuberculous regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59:13-32.
81. Medical and Health Department, Hong Kong. Annual Report, 1985.
82. Editorial. Antibiotics and the liver. BMJ 1980; 1:1486-1487.
83. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4:83.
84. Singapore Tuberculosis Services/British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Am Rev Resp Dis 1977; 116:807.
85. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid associated hepatitis in 114 patients. Gastroenterology 1975; 69:289-302.
86. Advenier C, Saint-Aubin A, Gobert C, Hollin G, Albengres E, Tillement JP. Pharmacokinetics of isoniazid in the elderly. Br J Clin Pharm 1980; 10:167-169.
87. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17:968-975.
88. Dorken E, Grzybowski S, Allen EA. Significance of the tuberculin test in the elderly. Chest 1987; 92:237-240.